# US 2013/0273115 A1 · Injectable filler

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273115 A1
- Document ID: US20130273115A1
- Status: Published application
- Kind: A1
- Application number: 13/353,316
- Filed: 2012-01-18
- Published: 2013-10-17
- Earliest claimed: 2011-11-11
- Inventors: Phi Nguyen; Loc Phan; Bao Tran
- Web page: https://patentgrep.com/patent/US20130273115A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 8/42: Amides
- A61K 8/45: Derivatives containing from 2 to 10 oxyalkylene groups
- A61K 8/63: Steroids; Derivatives thereof
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/20: Polysaccharides
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61Q 19/08: Anti-ageing preparations
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 2800/91: Injection
- A61L 2300/602: Type of release, e.g. controlled, sustained, slow
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/04: for mammary reconstruction
- A61L 2430/34: for soft tissue reconstruction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Systems and method are disclosed for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a predetermined controlled release of a pharmaceutical substance to modulate soft tissue response to the polymer, the polymer having at least one phase cross-linked, glycosaminoglycan in a physiological buffer solution; and augmenting soft tissue with the biocompatible cross-linked polymer.

## Claims

### Claim 1

A method for cosmetic augmentation, comprising:
forming a biocompatible cross-linked polymer having a multi-phase mixture with a predetermined controlled release of a pharmaceutical substance to modulate soft tissue response to the polymer, the polymer having at least one phase cross-linked, glycosaminoglycan in a physiological buffer solution; and
augmenting soft tissue with the biocompatible cross-linked polymer.

### Claim 2 (depends on 1)

The method of claim 1, comprising injecting the biocompatible cross-linked polymer in a minimally invasive manner.

### Claim 3 (depends on 1)

The method of claim 1, comprising dermally injecting the biocompatible cross-linked polymer in a minimally invasive manner.

### Claim 4 (depends on 1)

The method of claim 1, comprising using a syringe to inject the biocompatible cross-linked polymer under the skin in a minimally invasive manner.

### Claim 5 (depends on 1)

The method of claim 1, comprising using a syringe to inject the biocompatible cross-linked polymer in a breast or a buttock in a minimally invasive manner.

### Claim 6 (depends on 1)

The method of claim 1, comprising using a syringe to inject the biocompatible cross-linked polymer under soft tissue in a minimally invasive manner.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polymer comprises one of: collagens, hyaluronic acids, celluloses, proteins, saccharides, an extracellular matrix of a biological system.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polymer comprises a thermoplastic, comprising converting the polymer to a thermoset.

### Claim 9 (depends on 1)

The method of claim 1, comprising using cross linkers and forming thermoset polymers or to form cross linked copolymers by crosslinking with other polymer species using multifunctional monomers.

### Claim 10 (depends on 1)

The method of claim 1, comprising implanting a composition with a biocompatible viscoelastic gel slurry comprising a two phase mixture, a first phase being a particulate biocompatible gel phase, said gel phase comprising a chemically cross-linked glycosaminoglycan, or said glycosaminoglycan chemically co-cross-linked with at least one other polymer selected from the group consisting of polysaccharides and proteins, said gel phase being swollen in a physiologically acceptable aqueous medium and being uniformly distributed in the second phase, said second phase comprising a polymer solution of a hydrophilic biocompatible polymer selected from the group consisting of polysaccharides, polyvinylpyrrolidone and poly ethyleneoxide in said physiologically acceptable aqueous medium, and wherein the polymer solution in the two phase mixture constitutes from 0.01 to 99.5% and the gel phase constitutes the remainder into a part of a living body where such augmentation is desired.

### Claim 11 (depends on 1)

The method of claim 1, comprising adding a substance to the composition for biocompatibility

### Claim 12 (depends on 1)

The method of claim 1, comprising controlling drug releases at predetermined timing according physiological events.

### Claim 13 (depends on 1)

The method of claim 1, comprising carrying the drug by the biocompatible and biodegradable polymers.

### Claim 14 (depends on 1)

The method of claim 1, comprising dispensing the drug uniformly throughout a material matrix of the biodegradable polymer.

### Claim 15 (depends on 1)

The method of claim 1, comprising housing the drug in a core-shell structure and drug release is based on diffusion and solubility.

### Claim 16 (depends on 1)

The method of claim 1, comprising providing a polymer that carries the drug including one of: polylactide (PLA), polyglycolide (PGA) and copolymers of PLA/PGA tailored to meet mechanical performance and resorption rates required for applications ranging from non-structural drug delivery polymer applications to biodegradable screws or anchors.

### Claim 17 (depends on 1)

The method of claim 1, comprising releasing drug into a biological environment at the same rate as a polymer rate of degradation and the rate of drug diffusing from a polymer matrix.

### Claim 18 (depends on 1)

The method of claim 1, comprising blending a drug carrier polymer composition and a filler polymer composition at a predetermined ratio.

### Claim 19 (depends on 1)

The method of claim 1, comprising adding one or more of: an anesthetics, a lidocaine, a compound to reduce or eliminate acute inflammatory reactions, or a composition selected from the group consisting of steroids, corticosteroids, dexamethasone, triamcinolone.

### Claim 20 (depends on 1)

The method of claim 1, comprising providing a slow release substance or a fast releasing substance.

### Claim 21 (depends on 1)

The method of claim 1, comprising providing one or more predetermined lengths of delay time before the drug starts to release.
